RIFADIN 150 MG
RIFAMPIN : 150 MG · DIN 02091887 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is RIFADIN?
RIFADIN 150 MG contains RIFAMPIN : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02091887, held by SANOFI-AVENTIS CANADA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RIFADIN used for?
Treatment of tuberculosis (concomitantly with other drugs). Prophylaxis of bacterial meningitis or carriage of N. meningitidis or H. influenza b in exposed persons.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02091887 |
|---|---|
| Brand name | RIFADIN |
| Generic / active ingredient | RIFAMPIN : 150 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 150 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J04AB02 RIFAMPICIN |
| AHFS class | 08:16.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Jan-2021 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Administer 1 hour before meals. For TB, use with other drugs. Prophylaxis: 600 mg bid for 2 days (N. meningitidis) or 600 mg daily for 4 days (H. influenzae). Resume with small increasing doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions 150 mg & 300 mg capsules).
Contraindications
Jaundice with reduced bilirubin excretion; hypersensitivity to rifamycins; premature/newborn infants; lactation; concurrent use with saquinavir/ritonavir.
Warnings and precautions
Liver dysfunction/hepatotoxicity; severe hypersensitivity (DRESS); severe bullous skin reactions (SJS, TEN); Clostridium difficile-associated disease (CDAD); vitamin K dependent coagulopathy.
What can be used instead?
Other Canadian products sharing ATC code J04AB02 RIFAMPICIN. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROFACT | 150 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00393444 |
| ROFACT | 300 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00343617 |
| RIFADIN | 300 MG | CAPSULE | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02092808 |
| RIFADIN CAP 300MG | 300 MG | CAPSULE | MERRELL DOW PHARMACEUTICALS (CANADA) INC., DIVISION OF MMDC | CANCELLED POST MARKET | DIN 00580384 |
Who else supplies RIFAMPICIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIFAMPICIN appears in 4654 registered pack listings across 9 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.